Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Study ID
NCT04390945
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab combined with concurrent radiotherapy and chemotherapy

Study Details

China is a country with a large incidence of esophageal cancer. The prevalence and mortality rate of esophageal cancer in China ranks fifth in the world. However, due to China's huge population base, new patients with esophageal cancer and deaths account for about 55% of the world. This study aimed to explore the efficacy and safety of Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer.

Key Dates

Start date
Dec 1, 2021
Status verified
Jan 2022
Primary completion
Oct 31, 2023
Completion
Aug 31, 2024

Study Design

Enrollment
62 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy
    Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) Simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F) Chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks).

Primary Outcome Measure

Progression-free survival，PFS [ Time Frame: 9 months ]

Central Contacts

Related Studies